15
research focus
cannapatientcare.com october/november 2021
|
cannabis patient care
as antitumor agents," Oncotarget. DOI: 10.1016/j.jsps.2019.01.005. Retrieved
from www.semanticscholar.org/paper/The-heterogeneity-and-complexity-of-
Cannabis-as-Baram-Peled/ca3a543b372e5474439fbfc4bd5cbc4f41e904cf (2019).
(6) J. Glogauer and J. Blay, "Cannabinoids, Their Cellular Receptors,
and Effects on the Invasive Phenotype of Carcinoma and
Metastasis" Cancer Reports. DOI: 10.1002/cnr2.1475. Retrieved from
onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.1475 (2021).
(7) Treatment Side Effects (2021, Mar 29). Breastcancer.org. Retrieved
from www.breastcancer.org/treatment/side_effects.
(8) J. Aviram, et al, "Short-Term Medical Cannabis Treatment Regimens
Produced Beneficial Effects among Palliative Cancer Patients,"
Pharmaceuticals. DOI: 10.3390/ph13120435. Retrieved from www.
researchgate.net/publication/346484148 (2020).
(9) M. Weiss, et al "A survey of cannabis use for symptom palliation in breast
cancer patients by age and stage," J. of Clinical Oncology. Retrieved from
ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12108 (2020).
(10) A.I. Fraguas-Sánchez, A. Fernández-Carballido, R. Simancas-Herbada, C. Martin-
Sabroso, and A.I. Torres-Suárez, "CBD loaded microparticles as a potential
formulation to improve paclitaxel and doxorubicin-based chemotherapy
in breast cancer," International Journal of Pharmaceutics. DOI: 10.1016/j.
ijpharm.2019.118916. Retrieved from pubmed.ncbi.nlm.nih.gov/31811927/ (2019).
(11) M.M. Caffarel, C. Andradas, E. Pérez-Gómez, M. Guzmán, and C. Sánchez,
"Cannabinoids: A new hope for breast cancer therapy?" Cancer Treatment
Reviews. DOI: 10.1016/j.ctrv.2012.06.005. Retrieved from www.semanticscholar.
org/paper/Cannabinoids%3A-a-new-hope-for-breast-cancer-therapy-
Caffarel-Andradas/998e07defe9c75215c34acae8118718f0e5bf55f (2012).
(12) M. Caffarel, et al, "D9-Tetrahydrocannabinol Inhibits Cell Cycle Progression
in Human Breast Cancer Cells through Cdc2 Regulation," Cancer
Research. DOI: 10.1158/0008-5472.CAN-05-4566. Retrieved from cancerres.
aacrjournals.org/content/canres/66/13/6615.full.pdf (2006).
(13) Breast Cancer Ploidy and Cell Proliferation. (2019, Sep 20) American
Cancer Society. Retrieved from www.cancer.org/cancer/breast-cancer/
understanding-a-breast-cancer-diagnosis/ploidy-and-cell-proliferation.html.
(14) L. Dobovišek, et al, "Cannabinoids and Hormone Receptor-Positive Breast Cancer
Treatment," Cancers. DOI: 10.3390/cancers12030525. Retrieved from https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC7139952/pdf/cancers-12-00525.pdf (2020).
(15) D. Ladin, et al, "Preclinical and Clinical Assessment of Cannabinoids
as Anti-Cancer Agents," Frontiers in Pharmacology. DOI: 10.3389/
fphar.2016.00361. Retrieved from www.ncbi.nlm.nih.gov/pmc/
articles/PMC5054289/pdf/fphar-07-00361.pdf (2016).
(16) M. Elbaz, et al, "Modulation of the Tumor Microenvironment and
Inhibition of EGF/EGFR Pathway; Novel Anti-tumor Mechanisms Of
Cannabidiol In Breast Cancer," Molecular Oncology. DOI: 10.1016/j.
molonc.2014.12.010. Retrieved from www.meta.org/papers/modulation-
of-the-tumor-microenvironment-and/25660577 (2015).
(17) R. Murase, et al, "Targeting multiple cannabinoid anti-tumour pathways
with a resorcinol derivative leads to inhibition of advanced stages
of breast cancer," British J. of Pharmacology. DOI:10.1111/bph.12803.
Retrieved from pubmed.ncbi.nlm.nih.gov/24910342/ (2014).
(18) Apoptosis. (n.d.) National Cancer Institute. Retrieved from
www.cancer.gov/publications/dictionaries/cancer-terms/def/apoptosis.
(19) A. Tomko, et al, "Antitumor Activity of Abnormal Cannabidiol and Its
Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer,"
Frontiers in Pharmacology. DOI: 10.3389/fphar.2019.01124. Retrieved from
www.frontiersin.org/articles/10.3389/fphar.2019.01124/full (2019).
(20) A. Sultan, M. Marie, and S. Sheweita, "Novel mechanism of cannabidiol-
induced apoptosis in breast cancer cell lines," The Breast. DOI: 10.1016/j.
breast.2018.06.009. Retrieved from pubmed.ncbi.nlm.nih.gov/30007266/ (2018).
(21) A. Shrivastava, et al, "Cannabidiol Induces Programmed Cell Death in
Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis
and Autophagy," Mol. Cancer Ther. DOI: 10.1158/1535-7163.MCT-10-
1100. Retrieved from pubmed.ncbi.nlm.nih.gov/21566064/ (2011).
(22) Angiogenesis. (n.d.) National Cancer Institute. Retrieved from
www.cancer.gov/publications/dictionaries/cancer-terms/def/angiogenesis.
(23) P. Picardi, E. Ciaglia, M. Proto, and S. Pisanti, "Anandamide inhibits breast
tumor-induced angiogenesis," Transl. Med. UniSa. Retrieved from elea.
unisa.it/jspui/bitstream/10556/1634/1/Picardi_Ciaglia_Proto_Pisanti_
Anandamide_inhibits_breast_tumor_induced_angiogenesis.pdf (2014).
(24) N. Farsandaj, M. Ghahremani, and S. Ostad, "Role of cannabinoid and
vanilloid receptors in invasion of human breast carcinoma cells," J. Environ.
Pathol. Toxicol. Oncol. DOI: 10.1615/jenvironpatholtoxicoloncol.2013005859.
Retrieved from pubmed.ncbi.nlm.nih.gov/23394450/ (2012).
(25) P. Friedl and K. Wolf, "Tumour-cell invasion and migration: diversity
and escape mechanisms," Nature Reviews Cancer. Retrieved from
www.nature.com/articles/nrc1075/briefing/signup/ (2003).
(26) S. Takeda, et al, "Cannabidiolic acid, a major cannabinoid in fiber-
type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell
migration," Toxicology Letters. DOI: 10.1016/j.toxlet.2012.08.029.
Retrieved from pubmed.ncbi.nlm.nih.gov/22963825/ (2012).
(27) S. Takeda, et al, "D9-Tetrahydrocannabinol enhances MCF-7 cell
proliferation via cannabinoid receptor-independent signaling,"
Toxicology. DOI: 10.1016/j.tox.2007.12.019. Retrieved from www.sciencedirect.
com/science/article/abs/pii/S0300483X07008566 (2008).
(28) R. McKallip, M. Nagarkatti, and P. Nagarkatti, "∆-9-Tetrahydrocannabinol
Enhances Breast Cancer Growth and Metastasis by Suppression of the
Antitumor Immune Response," J. Immunol. DOI: 10.4049/jimmunol.174.6.3281.
Retrieved from www.jimmunol.org/content/174/6/3281 (2005).
(29) B. Dariš, M. Verboten, Z. Knez, and P. Ferk, "Cannabinoids in cancer
treatment: Therapeutic potential and legislation," Bosnian J. of Basic
Medical Sciences. DOI: 10.17305/bjbms.2018.3532. Retrieved from www.ncbi.
nlm.nih.gov/pmc/articles/PMC6387667/pdf/BJBMS-19-14.pdf (2018).
(30) T. Kisková, et al, Retrieved from Future Aspects for Cannabinoids
in Breast Cancer Therapy. International J of Molecular Sciences.
DOI: 10.3390/ijms20071673. Retrieved from www.ncbi.nlm.nih.gov/
pmc/articles/PMC6479799/pdf/ijms-20-01673.pdf (2019).
About the author
RUTH FISHER, PHD, is a systems design researcher and an-
alyst. She analyzes markets to determine how environments
shape outcomes. She is co-founder of CannDynamics, Inc.,
and author of The Medical Cannabis Primer and Winning the
Hardware-Software Game: Using Game Theory to Optimize
the Pace of New Technology Adoption. Dr. Fisher has worked
in the technology and healthcare sectors on behalf of tech-
nology companies, early-stage researchers, physicians, and
technology start-ups.
